|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007138,
umls-concept:C0008838,
umls-concept:C0025677,
umls-concept:C0030705,
umls-concept:C0030956,
umls-concept:C0042196,
umls-concept:C0042670,
umls-concept:C0085752,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0231175,
umls-concept:C0920321,
umls-concept:C1709510
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2011-9-2
|
|
pubmed:abstractText |
• To investigate the safety and immune responses of 12 consecutive weeks of once-weekly personalized peptide vaccine (PPV) administration in patients with advanced urothelial carcinoma (UC) for whom therapy with methotrexate, vinblastine, adriamycin and cisplatin (MVAC) has failed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1464-410X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
108
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
831-8
|
|
pubmed:meshHeading |
pubmed-meshheading:21166757-Adult,
pubmed-meshheading:21166757-Aged,
pubmed-meshheading:21166757-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21166757-Cancer Vaccines,
pubmed-meshheading:21166757-Cisplatin,
pubmed-meshheading:21166757-Disease-Free Survival,
pubmed-meshheading:21166757-Doxorubicin,
pubmed-meshheading:21166757-Drug Administration Schedule,
pubmed-meshheading:21166757-Drug Resistance, Neoplasm,
pubmed-meshheading:21166757-Feasibility Studies,
pubmed-meshheading:21166757-Female,
pubmed-meshheading:21166757-HLA Antigens,
pubmed-meshheading:21166757-Humans,
pubmed-meshheading:21166757-Immunity, Cellular,
pubmed-meshheading:21166757-Immunity, Humoral,
pubmed-meshheading:21166757-Immunoglobulin G,
pubmed-meshheading:21166757-Individualized Medicine,
pubmed-meshheading:21166757-Male,
pubmed-meshheading:21166757-Methotrexate,
pubmed-meshheading:21166757-Middle Aged,
pubmed-meshheading:21166757-Remission Induction,
pubmed-meshheading:21166757-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:21166757-Tomography, X-Ray Computed,
pubmed-meshheading:21166757-Urologic Neoplasms,
pubmed-meshheading:21166757-Vaccines, Subunit,
pubmed-meshheading:21166757-Vinblastine
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
|
|
pubmed:affiliation |
Department of Urology, Kitasato University School of Medicine, Japan.
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase I
|
